MiNK Therapeutics, Autonomous Therapeutics enter research collaboration

MiNK Therapeutics and Autonomous Therapeutics announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous’ precision encrypted RNA technology and MiNK’s innovative iNKT cell therapies, MiNK-215 and agenT-797. The companies will evaluate these technologies in metastatic solid tumor models. The goal is to develop novel therapies that effectively target metastatic cancer cells in patients while avoiding healthy cells-a challenge that existing cancer medicines have not been able to overcome. Based on the results, the companies plan to launch a Phase 1 clinical trial in patients with treatment-refractory metastatic solid tumors, including microsatellite stable colorectal cancers.